The best ideas happen when the right people work together.
At Curebound, collaboration is everything.
Our funding model engineers collaboration across multiple disciplines and institutions. We provide early phase, follow-on and clinical trial funding to cross-institutional research teams that bring together physician scientists, clinical researchers, and basic-science researchers to work in partnership on a specific challenge in cancer research.
This combination of bringing clinical data to early, basic discovery research is unique to Curebound, and creates collaborations that otherwise would not exist.
Curebound considers applications for all types of cancer research projects and can curate opportunities for individuals to invest in specific areas of research. For philanthropists and organizations looking to direct funding toward exploration of a particular cancer type or treatment area, Curebound’s world class Scientific Advisory Board (SAB) will make discerning investments.
Curebound funds three types of cancer research grants:
• First time seed grants for high-risk, high-reward, collaborative, translational research. Ideas are innovative and in the early phases, where smaller grants of up to $250,000 can make a big impact in advancing research
• Discovery Grants are one-time grants and will be determined by the peer-review process established by Padres Pedal the Cause and implemented by the six beneficiary institutions.
• Larger and potentially multi-year gifts ranging from $250,000 to $1,000,000 that provide follow on funding to Discovery Grants that have met pre-determined goals e.g., demonstrated efficacy and have a clear plan of action e.g., to demonstrate innovation and differentiation with respect to standard-of-care and progress to meaningful clinical milestones, along with a well-supported budget.
• The SAB will also consider targeted funding for major public health and population studies as they align with Curebound investment pillars.
• Innovative, game changing, multidisciplinary projects that receive major funding ranging from $1,000,000 to $5,000,000, administered over multiple years.
• Cure Prize concepts will be determined collectively by the SAB and will seek to foster collaborations with and invoke matching funds from corporate industry partners, private investors, major federal grants and grants from other foundations.
Curebound raises and invests strategic funding in translational cancer research projects aimed at accelerating new discoveries to clinical application. The full index of our research portfolio is available below.
Current immune checkpoint inhibitors generally only generate anti-tumor responses in about 15% breast cancer patients already presenting recurrent metastatic lesions. Here we propose to establish new breast tumor models to study whether and how crosstalk between tumor cells and B-cells impact anti-tumor immunity and tumor responses to immune checkpoint inhibitors.Read More
After cancer treatment, female pediatric, adolescent and young adult (AYA) cancer survivors experience more infertility and ovarian failure, which are devastating but preventable outcomes. This study will yield rigorous pilot data on innovative, scalable telehealth interventions to preserve the reproductive futures of young cancer patients, expand remote delivery of quality oncology care, and bridge silos to provide equitable multi-disciplinary care of oncology patients.Read More
Cancer immunotherapies have led to major treatment breakthroughs for a number of different cancers, but the majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses…Read More
High-grade gliomas (pHGG) are the most common brain tumors in children and carry poor prognosis, hence there is significant unmet need for improved treatment.The primary aims of this project are: 1) To elucidate the functional significance of CD8+ tissue-resident memory cells in anti-tumor immune responses in pHGG; and 2) To Identify molecular mechanisms driving differentiation and function of HGG-infiltrating CD8+ TRM cells.Read More
The immune cells of the human body secrete a group of proteins called “cytokines” that have specific effects on the interactions and communication between cells. A subset of these, Type I interferons (IFN-I) “interfere” with growth and promote the death of tumors. We propose to develop methods to identify and verify compounds that potently and selectively block this feedback suppression that could become the basis for novel cancer therapeutics.Read More
Children with high-risk and recurrent solid tumors have extremely poor outcomes despite aggressive therapy, and new treatments are desperately needed.Read More
In diseases called ribosomopathies, kids are born with genetic errors that disrupt ribosomes, which are the machines our cells use to make protein. This causes problems in multiple organ systems, especially the blood. Patients often develop reduced blood cell counts and are at increased risk for developing leukemia and other cancers that respond poorly to chemotherapy and treatment.Read More
Metastatic castration resistant prostate cancer (CRPC) is a lethal disease that claims 30,000 lives annually in the U.S. Although current approved drugs will slow the growth of metastatic CRPC, development of drug resistance—and cancer progression—is inevitable.Read More
Medulloblastoma is the most common malignant brain tumor in children. Although significant advances have been made in treating medulloblastoma, many patients still die from the disease, and those who survive suffer severe long-term side effects from therapy.Read More